Investment Analysts’ Weekly Ratings Updates for Krystal Biotech (KRYS)

A number of research firms have changed their ratings and price targets for Krystal Biotech (NASDAQ: KRYS):

• 1/9/2026 – Krystal Biotech had its “buy” rating reaffirmed by analysts at Cowen Inc.
• 1/9/2026 – Krystal Biotech had its “buy” rating reaffirmed by analysts at HC Wainwright. They now have a $310.00 price target on the stock, up previously from $240.00.
• 1/9/2026 – Krystal Biotech had its price target raised by analysts at TD Cowen from $202.00 to $306.00. They now have a “buy” rating on the stock.
• 1/7/2026 – Krystal Biotech was upgraded by analysts at Zacks Research from a “hold” rating to a “strong-buy” rating.
• 1/6/2026 – Krystal Biotech was upgraded by analysts at Citigroup Inc. from a “neutral” rating to a “buy” rating. They now have a $309.00 price target on the stock, up previously from $198.00.
• 12/29/2025 – Krystal Biotech had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/22/2025 – Krystal Biotech had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/15/2025 – Krystal Biotech had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/8/2025 – Krystal Biotech had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 12/1/2025 – Krystal Biotech had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/25/2025 – Krystal Biotech had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/19/2025 – Krystal Biotech had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.
• 11/13/2025 – Krystal Biotech had its “hold (c+)” rating reaffirmed by analysts at Weiss Ratings.

Insider Buying and Selling at Krystal Biotech

In related news, insider Suma Krishnan sold 25,000 shares of the firm’s stock in a transaction that occurred on Thursday, December 4th. The stock was sold at an average price of $220.16, for a total value of $5,504,000.00. Following the transaction, the insider directly owned 1,413,711 shares of the company’s stock, valued at approximately $311,242,613.76. This trade represents a 1.74% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. Corporate insiders own 13.70% of the company’s stock.

Krystal Biotech, Inc is a clinical-stage biotechnology company focused on developing gene therapies for rare dermatological diseases. Headquartered in Pittsburgh, Pennsylvania, the company applies proprietary viral vector delivery technology to enable topical administration of corrective genes directly to the skin. By targeting the underlying genetic causes of inherited skin disorders, Krystal Biotech seeks to address areas of high unmet medical need with potentially transformative treatments.

The company’s lead product candidate, KB103, is designed to deliver a functional COL7A1 gene to patients with dystrophic epidermolysis bullosa (DEB), a severe and often debilitating blistering condition.